Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
about
Maraviroc: a review of its use in HIV infection and beyondBone loss in HIV: a contemporary review.Tenofovir and bone health.Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.Backbones versus core agents in initial ART regimens: one game, two players.Bone health and HIV in resource-limited settings: a scoping review.Neurocognition with maraviroc compared with tenofovir in HIV.Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.HIV Infection and Bone Abnormalities.Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.Association between a suppressor combined antiretroviral therapy containing Maraviroc and the hepatitis B virus vaccine response.The HIV co-receptor CCR5 regulates osteoclast function.Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens.Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination
P2860
Q26778504-098BE74F-B381-4FCA-9DCE-C00EB12D6755Q36330955-B33F007E-3983-40F8-AC26-B07F04AE9034Q36833961-2D45D998-4B9A-4023-88D0-9F4E7D8E42D8Q36868170-B8828FD0-D296-4E53-B975-EBF566CAA5ABQ38690825-B1306287-2142-437A-AEC3-2DEAA976EFBBQ38792298-E099D209-953C-4691-B3C2-7B58B3D3CC27Q39402373-A0B49F99-67E0-46F4-B4E5-57D061DAF240Q39696831-95E09E44-8C66-4178-8D27-6870AB9F9AC8Q40084752-C02A5C16-FFF6-41AE-A70D-55D4E8336E14Q40267569-D5678A45-FE26-42F3-AD9F-AD33F7195608Q40464768-D7BF73A7-2DA6-4A89-9EEA-A8B2AEFAAE62Q40668927-F9F138BD-3C77-4B74-8154-EE9A7C10779AQ41877618-3FAC7B13-D357-42C7-9D11-94F2F84A4BABQ45170011-21F0344F-52C5-444E-8ECE-5120901F7D23Q45325503-469466E2-59D7-449D-96FC-5814D3BBBB8FQ47126167-E5EF53FD-456C-420D-A3A7-1DACBD3A247BQ47562735-1CBBB0DD-8335-4B72-933C-CBA946110542Q58694800-2188D5D6-8997-4DF2-A1F4-AFD82DFB32F1
P2860
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Less Bone Loss With Maraviroc- ...... ical Trials Group A5303 Study.
@ast
Less Bone Loss With Maraviroc- ...... ical Trials Group A5303 Study.
@en
type
label
Less Bone Loss With Maraviroc- ...... ical Trials Group A5303 Study.
@ast
Less Bone Loss With Maraviroc- ...... ical Trials Group A5303 Study.
@en
prefLabel
Less Bone Loss With Maraviroc- ...... ical Trials Group A5303 Study.
@ast
Less Bone Loss With Maraviroc- ...... ical Trials Group A5303 Study.
@en
P2093
P2860
P356
P1476
Less Bone Loss With Maraviroc- ...... ical Trials Group A5303 Study.
@en
P2093
AIDS Clinical Trials Group A5303 Study Team
Alan Landay
Athe Tsibris
Babafemi O Taiwo
Baiba Berzins
Ellen S Chan
Heather Ribaudo
Igho Ofotokun
Karin L Klingman
Kevin Robertson
P2860
P304
P356
10.1093/CID/CIV455
P407
P577
2015-06-09T00:00:00Z